Is BACK PAIN a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed BACK PAIN.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 79 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported BACK PAIN to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and BACK PAIN. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause BACK PAIN, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes BACK PAIN. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if BACK PAIN ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing BACK PAIN: 79
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where BACK PAIN is a reported side effect: 2.3731%

FDA reports of any drug causing BACK PAIN : 63655
Average percentage for all medicated patients where BACK PAIN is reported as a complication: 0.3990%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with BACK PAIN:

FOSAMAX (10530 patients)
VIOXX (6233 patients)
ASPIRIN (5997 patients)
FORTEO (5274 patients)
ZOMETA (4875 patients)
LIPITOR (3450 patients)
SEROQUEL (3432 patients)
PREDNISONE (3019 patients)
ACCUTANE (2935 patients)
NEXIUM (2874 patients)
ENBREL (2847 patients)
HUMIRA (2824 patients)
AREDIA (2726 patients)
NEURONTIN (2513 patients)
SYNTHROID (2501 patients)
LISINOPRIL (2497 patients)
AVONEX (2420 patients)
LASIX (2340 patients)
PRILOSEC (2285 patients)
XANAX (2258 patients)
AMBIEN (2198 patients)
COUMADIN (2189 patients)
OXYCONTIN (2167 patients)
TYSABRI (2154 patients)
CELEBREX (2080 patients)
REMICADE (2049 patients)
VITAMIN D (1963 patients)
FOLIC ACID (1948 patients)
METHOTREXATE (1914 patients)
VICODIN (1882 patients)
PROTONIX (1876 patients)
LYRICA (1876 patients)
ATENOLOL (1866 patients)
ZOLOFT (1860 patients)
HYDROCHLOROTHIAZIDE (1840 patients)
OMEPRAZOLE (1823 patients)
ZOCOR (1798 patients)
PERCOCET (1771 patients)
LEVAQUIN (1711 patients)
PLAVIX (1684 patients)
DURAGESIC-100 (1647 patients)
FUROSEMIDE (1636 patients)
IBUPROFEN (1627 patients)
SIMVASTATIN (1617 patients)
ALBUTEROL (1600 patients)
NORVASC (1599 patients)
TOPROL-XL (1585 patients)
CRESTOR (1570 patients)
PREVACID (1532 patients)
CALCIUM (1520 patients)
DEXAMETHASONE (1509 patients)
ACETAMINOPHEN (1493 patients)
ATIVAN (1476 patients)
CYMBALTA (1421 patients)
GABAPENTIN (1418 patients)
LEXAPRO (1417 patients)
LORTAB (1387 patients)
SOLIRIS (1377 patients)
PAXIL (1373 patients)
LORAZEPAM (1365 patients)
DIGOXIN (1355 patients)
ZOFRAN (1340 patients)
POTASSIUM CHLORIDE (1340 patients)
MIRENA (1311 patients)
DECADRON (1305 patients)
OXYCODONE HCL (1265 patients)
PROZAC (1243 patients)
EFFEXOR (1222 patients)
DIOVAN (1203 patients)
LEVOTHYROXINE SODIUM (1202 patients)
BONIVA (1194 patients)
PREMARIN (1194 patients)
FLEXERIL (1173 patients)
MORPHINE (1170 patients)
HEPARIN SODIUM INJECTION (1138 patients)
SANDOSTATIN LAR (1136 patients)
METFORMIN HCL (1135 patients)
PREDNISONE TAB (1106 patients)
ALENDRONATE SODIUM (1082 patients)
KLONOPIN (1033 patients)
REVLIMID (1032 patients)
ADVAIR DISKUS 100/50 (1023 patients)
WELLBUTRIN (1021 patients)
MULTI-VITAMINS (1013 patients)
ALPRAZOLAM (1013 patients)
FOSAMAX PLUS D (990 patients)
ALLOPURINOL (987 patients)
DILAUDID (982 patients)
AMOXICILLIN (980 patients)
ACTONEL (972 patients)
WARFARIN SODIUM (968 patients)
CLONAZEPAM (955 patients)
SINGULAIR (948 patients)
LANTUS (947 patients)
CELEXA (946 patients)
NITROGLYCERIN (942 patients)
VALIUM (931 patients)
PREDNISOLONE (928 patients)
CHANTIX (922 patients)
DEFINITY (919 patients)
YAZ (912 patients)
METOPROLOL TARTRATE (912 patients)
YASMIN (904 patients)
BYETTA (889 patients)
ZANTAC (870 patients)
SPIRIVA (852 patients)
ZYRTEC (852 patients)
TAXOTERE (829 patients)
DIAZEPAM (829 patients)
ARIMIDEX (829 patients)
ALLEGRA (819 patients)
FENTANYL (818 patients)
CALCIUM CARBONATE (807 patients)
CHEMOTHERAPEUTICS NOS (789 patients)
MORPHINE SULFATE (786 patients)
REGLAN (779 patients)
COREG (774 patients)
TRAZODONE HCL (773 patients)
FEMARA (762 patients)
TRAMADOL HCL (760 patients)
GLUCOPHAGE (759 patients)
ZETIA (755 patients)
HYDROCODONE (744 patients)
FLOMAX (732 patients)
INSULIN (730 patients)
VITAMIN E (729 patients)
MOTRIN (727 patients)
TYLENOL (723 patients)
COLACE (721 patients)
HYDROCODONE BITARTRATE (721 patients)
TYLENOL (CAPLET) (720 patients)
EXJADE (717 patients)
FISH OIL (716 patients)
COMPAZINE (715 patients)
BENADRYL (715 patients)
ZYPREXA (714 patients)
SOMA (713 patients)
THALIDOMIDE (711 patients)
CIALIS (711 patients)
MULTI-VITAMIN (709 patients)
CIPROFLOXACIN (707 patients)
VITAMIN B-12 (700 patients)
LOVENOX (687 patients)
ULTRAM (674 patients)
METOPROLOL (673 patients)
ZITHROMAX (672 patients)
TAMOXIFEN CITRATE (668 patients)
RADIATION THERAPY (664 patients)
ASCORBIC ACID (664 patients)
NAPROXEN (659 patients)
PEPCID (653 patients)
ACTOS (651 patients)
ARANESP (651 patients)
AMLODIPINE (650 patients)
ELAVIL (649 patients)
COZAAR (644 patients)
ALEVE (CAPLET) (634 patients)
FLONASE (634 patients)
CLONIDINE (629 patients)
KEFLEX (629 patients)
LOPRESSOR (627 patients)
CLINDAMYCIN (625 patients)
AMITRIPTYLINE HCL (620 patients)
XELODA (616 patients)
REBIF (612 patients)
BACLOFEN (607 patients)
VELCADE (607 patients)
MIRALAX (593 patients)
RECLAST (592 patients)
PROMETHAZINE (586 patients)
TEMAZEPAM (584 patients)
AVELOX (584 patients)
MS CONTIN (583 patients)
CEPHALEXIN (573 patients)
FLUCONAZOLE (565 patients)
[THERAPY UNSPECIFIED] (565 patients)
CALCIUM (UNSPECIFIED) (561 patients)
SPIRONOLACTONE (558 patients)
ACYCLOVIR (555 patients)
SKELAXIN (551 patients)
GILENYA (540 patients)
RISPERDAL (540 patients)
CIPRO (538 patients)
PROLIA (537 patients)
FASLODEX (534 patients)
TAXOL (533 patients)
BEXTRA (527 patients)
AVANDIA (527 patients)
NIASPAN (527 patients)
GLIPIZIDE (522 patients)
OXYCODONE (518 patients)
LEVOXYL (512 patients)
AVASTIN (512 patients)
HUMALOG (508 patients)
IRON (506 patients)
METOCLOPRAMIDE (506 patients)
CLARITIN (505 patients)
PEGASYS (505 patients)
GLYBURIDE (504 patients)
POTASSIUM (501 patients)
ALEVE (496 patients)
NUVARING (496 patients)
ALTACE (496 patients)
MOBIC (491 patients)
CARBOPLATIN (490 patients)
VYTORIN (485 patients)
TOPAMAX (483 patients)
EVISTA (482 patients)
CYTOXAN (481 patients)
RANITIDINE (481 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about BACK PAIN and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.